The therapeutic potential of allosteric ligands for free fatty acid sensitive GPCRs

Current Topics in Medicinal Chemistry

Volumn 13, Issue 1, 2013, Pages 14-25

  Hudson, Brian D ^a   Ulven, Trond ^b   Milligan, Graeme ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Allosteric ligand; FFA1 3; Free fatty acid; GPCR; GPR120 orthosteric ligand; GPR84

Indexed keywords

4 AMINOBUTYRIC ACID; AMG 837; ANTIDIABETIC AGENT; DOCOSAHEXAENOIC ACID; FREE FATTY ACID RECEPTOR LIGAND; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 120; G PROTEIN COUPLED RECEPTOR 40 LIGAND; G PROTEIN COUPLED RECEPTOR LIGAND; GLUCAGON LIKE PEPTIDE 1; LIGAND; MUSCARINIC RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; ROSIGLITAZONE; TAK 875; UNCLASSIFIED DRUG;

ALLOSTERISM; CELL INFILTRATION; DESENSITIZATION; DRUG EFFICACY; DRUG POTENCY; FATTY ACID BLOOD LEVEL; FOLLOW UP; HUMAN; INFLAMMATION; KNOCKOUT GENE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STRUCTURE ACTIVITY RELATION; TACHYPHYLAXIS;

ALLOSTERIC REGULATION; ALLOSTERIC SITE; DRUG DESIGN; DRUGS, INVESTIGATIONAL; FATTY ACIDS, NONESTERIFIED; HUMANS; INFLAMMATION; LIGANDS; METABOLIC DISEASES; RECEPTORS, CELL SURFACE; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84876712334     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026611313010004     Document Type: Review

References (112)

1. Sawzdargo, M.; George, S.R.; Nguyen, T.; Xu, S.; Kolakowski, L.F.; O'Dowd, B.F. A cluster of four novel human G proteincoupled receptor genes occurring in close proximity to CD22 gene on chromosome 19q13.1. Biochem. Biophys. Res. Commun., 1997, 239(2), 543-547.
2. Stoddart, L.A.; Smith, N.J.; Milligan, G. International Union of Pharmacology. LXXI. Free fatty acid receptors FFA1,-2, and-3: pharmacology and pathophysiological functions. Pharmacol. Rev., 2008, 60(4), 405-417.
3. Briscoe, C.P.; Tadayyon, M.; Andrews, J.L.; Benson, W.G.; Chambers, J.K.; Eilert, M.M.; Ellis, C.E.; Elshourbagy, N.A.; Goetz, A.S.; Minnick, D.T.; Murdock, P.R.; Sauls, H.R. Jr.; Shabon, U.; Spinage, L.D.; Strum, J.C.; Szekers, P.G.; Tan, K.B.; Way, J.M.; Ignar, D.M.; Wilson, S.; Muir, A.I. The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids. J. Biol. Chem., 2003, 278(13), 11303-11311.
4. Itoh, Y.; Kawamata, Y.; Harada, M.; Kobayashi, M.; Fujii, R.; Fukusumi, S.; Ogi, K.; Hosoya, M.; Tanaka, Y.; Uejima, H.; Tanaka, H.; Maruyama, M.; Satoh, R.; Okubo, S.; Kizawa, H.; Komatsu, H.; Matsumura, F.; Noguchi, Y.; Shinohara, T.; Hinuma, S.; Fujisawa, Y.; Fujino, M. Free fatty acids regulate insulin secretion from pancreatic β cells through GPR40. Nature, 2003, 422(6928), 173-176.
5. Brown, A.J.; Goldsworthy, S.M.; Barnes, A.A.; Eilert, M.M.; Tcheang, L.; Daniels, D.; Muir, A.I.; Wigglesworth, M.J.; Kinghorn, I.; Fraser, N.J.; Pike, N.B.; Strum, J.C.; Steplewski, K.M.; Murdock, P.R.; Holder, J.C.; Marshall, F.H.; Szekeres, P.G.; Wilson, S.; Ignar, D.M.; Foord, S.M.; Wise, A.; Dowell, S.J. The Orphan G Protein-coupled Receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J. Biol. Chem. 2003, 278(13), 11312-11319.
6. Le Poul, E.; Loison, C.; Struyf, S.; Springael, J.Y.; Lannoy, V.; Decobecq, M.E.; Brezillon, S.; Dupriez, V.; Vassart, G.; Van Damme, J.; Parmentier, M.; Detheux, M. Functional characterization of human receptors for Short Chain fatty acids and their role in polymorphonuclear cell activation. J. Biol. Chem. 2003, 278(28), 25481-25489.
7. Nilsson, NE.; Kotarsky, K.; Owman, C.; Olde, B. Identification of a free fatty acid receptor, FFA2R, expressed on leukocytes and activated by short-chain fatty acids. Biochem. Biophys. Res. Commun. 2003, 303(4), 1047-1052.
8. Hirasawa, A.; Tsumaya, K.; Awaji, T.; Katsuma, S.; Adachi, T.; Tamada, M.; Sugimoto, Y.; Miyazaki, S.; Tsujimoto, G. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat. Med., 2005, 11(1), 90-94.
9. Oh, D.Y.; Talukdar, S.; Bae, E.J.; Imamura, T.; Morinaga, H.; Fan, W.; Li, P.; Lu, W.J.; Watkins, S.M.; Olefsky, J.M. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell. 2010, 142(5), 687-698.
10. Wang, J.; Wu, X.; Simonavicius, N.; Tian, H.; Ling, L. Mediumchain fatty acids as ligands for orphan G protein-coupled receptor GPR84. J. Biol. Chem., 2006, 281(45), 34457-34464.
11. Costanzi, S.; Neumann, S.; Gershengorn, M.C. Seven transmembrane spanning receptors for free fatty acids as therapeutic targets for diabetes mellitus: pharmacological, phylogenetic and drug discovery aspects. J. Biol. Chem. 2008, 283(24), 16269-16273.
12. Vangaveti, V.; Shashidhar, V.; Jarrod, G.; Baune, B.T.; Kennedy, R.L. Free fatty acid receptors: emerging targets for treatment of diabetes and its complications. Ther. Adv. Endocrinol. Metab., 2010, 1(4), 165-175
13. Hara, T.; Hirasawa, A.; Ichimura, A.; Kimura, I.; Tsujimoto, G. Free fatty acid receptors FFAR1 and GPR120 as novel therapeutic targets for metabolic disorders. J. Pharm. Sci., 2011, 100(9), 3594-3601.
14. Hudson, B.D.; Smith, N.J.; Milligan, G. Experimental challenges to targeting poorly characterized GPCRs: Uncovering the therapeutic potential for free fatty acid receptors. Adv. Pharmacol., 2011, 62, 175-218.
15. Talukdar, S.; Olefsky, J.M.; Osborn, O. Targeting GPR120 and other fatty acid-sensing GPCRs ameliorates insulin resistance and inflammatory diseases. Trends Pharmacol. Sci., 2011, 32(9), 543-50.
16. Holliday, N.D.; Watson, S.-J.; Brown, A.J.H. Drug discovery opportunities and challenges at G protein coupled receptors for long chain free fatty acids. Front. Endocrinol. 2:112.
17. Ulven, T. Short-chain free fatty acid receptors FFA2/GPR43 and FFA3/GPR41 as new potential therapeutic targets. Front. Endocrinol. 2012, 3, 111.
18. Tsujiha, Y.; Ito, R.; Suzuki, M.; Harada, A.; Negoro, N.; Yasuma, T.; Momose, Y.; Takeuchi, K. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats. J. Pharmacol. Exp. Ther., 2011, 339(1), 228-37.
19. Lin, D.C.; Zhang, J.; Zhuang, R.; Li, F.; Nguyen, K.; Chen, M.; Tran, T.; Lopez, E.; Lu, J.Y.; Li, X.N.; Tang, L.; Tonn, G.R.; Swaminath, G.; Reagan, J.D.; Chen, J.L.; Tian, H.; Lin, Y.J.; Houze, J.B.; Luo, J. AMG 837: A Novel GPR40/FFA1 agonist that enhances insulin secretion and lowers glucose levels in rodents. PLoS One., 2011, 6(11), e27270.
20. Burant, C.F.; Viswanathan, P.; Marcinak, J.; Cao, C.; Vakilynejad, M.; Xie, B.; Leifke, E. TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2.; randomized.; double-blind.; placebo-controlled trial. Lancet., 2012, 6736(11), 61879-61875.
21. Monod, J.; Changeux, J.P.; Jacob, F. Allosteric proteins and cellular control systems. J. Mol. Biol., 1963, 6, 306-329.
22. Monod, J.; Wyman, J.; Changeux, J.P. On the nature of allosteric transitions: a plausible model. J. Mol. Biol. 1965, 12, 88-118.
23. Christopoulos, A.; Kenakin, T. G protein-coupled receptor allosterism and complexing. Parmacol. Rev., 2002, 54(2), 323-374.
24. Milligan, G.; Smith, N.J. Allosteric modulation of heterodimeric Gprotein-coupled receptors. Trends Pharmacol. Sci., 2007, 28(12), 615-620.
25. May, L.T.; Leach, K.; Sexton, P.M.; Christopoulos, A. Allosteric modulation of G protein-coupled receptors. Annu. Rev. Pharmacol. Toxicol., 2007, 47, 1-51.
26. Conn, P.J.; Christopoulos, A.; Lindsley, C.W. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat. Rev. Drug Discov. 2009, 8(1), 41-54.
27. Smith, N.J; Milligan, G. Allostery at G protein-coupled receptor homo-and heteromers: uncharted pharmacological landscapes. Pharmacol. Rev., 2010, 62(4), 701-725.
28. Müller, C.E.; Schiedel, A.C.; Baqi, Y. Allosteric modulators of rhodopsin-like G protein-coupled receptors: opportunities in drug development. Pharmacol. Ther., 2012, 135(3), 292-315.
29. Price, M.R.; Baillie, G.L.; Thomas, A.; Stevenson, L.A.; Easson, M.; Goodwin, R.; McLean, A.; McIntosh, L.; Goodwin, G.; Walker, G.; Westwood, P.; Marrs, J.; Thomson, F.; Cowley, P.; Christopoulos, A.; Pertwee, R.G.; Ross, R.A. Allosteric modulation of the cannabinoid CB1 receptor. Mol. Pharmacol., 2005, 68(5), 1484-1495.
30. Mailman, R.B. GPCR functional selectivity has therapeutic impact. Trends Pharmacol. Sci., 2007, 28(8), 390-396.
31. Hudson, B.D.; Hébert, T.E.; Kelly, M.E.M. Ligand-and heterodimer-directed signaling of the CB(1) cannabinoid receptor. Mol. Pharmacol., 2010, 77(1), 1-9.
32. Kenakin, T. Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. Trends Pharmacol. Sci., 1995, 16(7), 232-238
33. Kenakin, T. Inverse, protean, and ligand-selective agonism: matters of receptor conformation. FASEB J., 2001, 15(3), 598-611.
34. Smith, N.J.; Bennett, K.A.; Milligan, G. When simple agonism is not enough: emerging modalities of GPCR ligands. Mol. Cell. Endocrinol., 2011, 331(2), 241-247.
35. Raehal, K.M.; Schmid, C.L.; Groer, C.E.; Bohn, L.M. Functional selectivity at the μ-opioid receptor: implications for understanding opioid analgesia and tolerance. Pharmacol. Rev. 2011, 63(4), 1001-1019.
36. Sigel, E.; Buhr, A. The benzodiazepine binding site of GABAA recepors. Trends Pharmacol. Sci., 1997, 18, 425-429.
37. Gregory, K.J.; Sexton, P.M.; Christopoulos A. Allosteric modulation of muscarinic acetylcholine receptors. Curr. Neuropharmacol., 2007, 5(3), 157-167.
38. Sheffler, D.J.; Gregory, K.J.; Rook, J.M.; Conn, P.J. Allosteric modulation of metabotropic glutamate receptors. Adv. Pharmacol. 2011, 62, 37-77.
39. Lin, D.C.; Guo, Q.; Luo, J.; Zhang, J.; Nguyen, K.; Chen, M.; Tran, T.; Dransfield, P.J.; Brown, S.P.; Houze, J.; Vimolratana, M.; Jiao, X.Y.; Wang, Y.; Birdsall, N.J.; Swaminath, G. Identification and pharmacological characterization of multiple allosteric binding sites on the free Fatty Acid 1 receptor. Mol. Pharmacol., 2012, 82(5), 843-859.
40. Palczewski, K.; Kumasaka, T.; Hori, T.; Behnke, C.A.; Motoshima, H.; Fox, B.A.; Le Trong, I.; Teller, D.C.; Okada, T.; Stenkamp, R.E.; Yamamoto, M.; Miyano, M. Crystal structure of rhodopsin: A G protein-coupled receptor. Science. 2000, 289(5480), 739-745.
41. Rasmussen, S.G.; Choi, H.J.; Rosenbaum, D.M.; Kobilka, T.S.; Thian, F.S.; Edwards, P.C.; Burghammer, M.; Ratnala, V.R.; Sanishvili, R.; Fischetti, R.F.; Schertler, G.F.; Weis, W.I.; Kobilka, B.K. Crystal structure of the human beta2 adrenergic G-proteincoupled receptor. Nature, 2007, 450(7168), 383-287.
42. Warne, T.; Serrano-Vega, M.J.; Baker, J.G.; Moukhametzianov, R.; Edwards, P.C.; Henderson, R.; Leslie, A.G.; Tate, C.G.; Schertler, G.F. Structure of a beta1-adrenergic G-protein-coupled receptor. Nature, 2008, 454(7203), 486-491.
43. Jaakola, V.P.; Griffith, M.T.; Hanson, M.A.; Cherezov, V.; Chien, E.Y.; Lane, J.R.; Ijzerman, A.P.; Stevens, R.C. The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science, 2008, 322(5905), 1211-1217.
44. Rasmussen, S.G.; DeVree, B.T.; Zou, Y.; Kruse, A.C.; Chung, K.Y.; Kobilka, T.S.; Thian, F.S.; Chae, P.S.; Pardon, E.; Calinski, D.; Mathiesen, J.M.; Shah, S.T.; Lyons, J.A.; Caffrey, M.; Gellman, S.H.; Steyaert, J.; Skiniotis, G.; Weis, W.I.; Sunahara, R.K.; Kobilka, B.K. Crystal structure of the β2 adrenergic receptor-Gs protein complex. Nature, 2011, 477(7366), 549-555.
45. Granier, S.; Manglik, A.; Kruse, AC.; Kobilka, T.S.; Thian, F.S.; Weis, W.I.; Kobilka, B.K. Structure of the δ-opioid receptor bound to naltrindole. Nature. 2012, 485(7398), 400-404.
46. Hanson, M.A.; Roth, C.B.; Jo, E.; Griffith, M.T.; Scott, F.L.; Reinhart, G.; Desale, H.; Clemons, B.; Cahalan, S.M.; Schuerer, S.C.; Sanna, M.G.; Han, G.W.; Kuhn, P.; Rosen, H.; Stevens, R.C. Crystal structure of a lipid G protein-coupled receptor. Science, 2012, 335(6070), 851-855.
47. Manglik, A.; Kruse, A.C.; Kobilka, T.S.; Thian, F.S.; Mathiesen, J.M.; Sunahara, R.K.; Pardo, L.; Weis, W.I.; Kobilka, B.K.; Granier, S. Crystal structure of the μ-opioid receptor bound to a morphinan antagonist. Nature., 2012, 485(7398), 321-326.
48. Park, S.H.; Das, B.B.; Casagrande, F.; Tian, Y.; Nothnagel, H.J.; Chu, M.; Kiefer, H.; Maier, K.; De Angelis, A.A.; Marassi, F.M.; Opella, S.J. Structure of the chemokine receptor CXCR1 in phospholipid bilayers. Nature, 2012, 491(7426), 779-783.
49. Thompson, A.A; Liu, W.; Chun, E.; Katritch, V.; Wu, H.; Vardy, E.; Huang, X.P.; Trapella, C.; Guerrini, R.; Calo, G.; Roth, B.L.; Cherezov, V.; Stevens, R.C. Structure of the nociceptin/orphanin FQ receptor in complex with a peptide mimetic. Nature, 2012, 485(7398), 395-399.
50. Costanzi, S. Homology modeling of class a G protein-coupled receptors. Methods Mol. Biol. 2012, 857, 259-279.
51. Levit, A.; Barak, D.; Behrens, M.; Meyerhof, W.; Niv, MY. Homology model-assisted elucidation of binding sites in GPCRs. Methods Mol. Biol., 2012, 914, 179-205.
52. Avlani, V.A.; Gregory, K.J.; Morton, C.J.; Parker, M.W.; Sexton, P.M.; Cristopoulos, A. Critical role for the second extracellular loop in the binding of both orthosteric and allosteric G proteincoupled receptors ligands. J. Biol. Chem., 2007, 282, 25677-25686.
53. Peeters, M.C.; Wisse, L.E.; Dinaj, A.; Vroling, B.; Vriend, G.; Ijzerman, A.P. The role of the second and third extracellular loops of the adenosine A1 receptor in activation and allosteric modulation. Biochem. Pharmacol., 2012, 84(1), 76-87.
54. Andrews, G.; Jones, C.; Wreggett, K.A. An intracellular allosteric site for a specific class of antagonists of the CC chemokine G protein-coupled receptors CCR4 and CCR5. Mol. Pharmacol., 2008, 73, 855-867.
55. Dowal, L.; Sim, D.S.; Dilks, J.R.; Blair, P.; Beaudry, S.; Denker, B.M.; Koukos, G.; Kuliopulos, A.; Flaumenhaft, R. Identification of an antithrombotic allosteric modulator that acts through helix 8 of PAR1. Proc. Nat. Acad. Sci. U.S.A., 2011, 108(7), 2951-2956.
56. Valant, C.; Felder, C.C.; Sexton, P.M.; Christopoulos, A. Probe dependence in the allosteric modulation of a G protein-coupled receptor: implications for detection and validation of allosteric ligand effects. Mol. Pharmacol., 2012, 81(1), 41-52.
57. Urwyler, S. Allosteric modulation of family C G-protein-coupled receptors: from molecular insights to therapeutic perspectives. Pharmacol. Rev., 2011, 63(1), 59-126.
58. Decker, M.; Holzgrabe, U. M1 muscarinic acetylcholine receptor allosteric modulators as potential therapeutics opportunities for treating Alzheimer's disease. Med. Chem. Commun., 2012, 3(7), 752-762.
59. Zhao, Z.; Wisnoski, D.D.; O'Brien, J.A.; Lemaire, W.; Williams, D.L, Jr.; Jacobson, M.A.; Wittman, M.; Ha, S.N.; Schaffhauser, H.; Sur, C.; Pettibone, D.J.; Duggan, M.E.; Conn, P.J.; Hartman, G.D.; Lindsley, C.W. Challenges in the development of mGluR5 positive allosteric modulators: the discovery of CPPHA. Bioorg. Med. Chem. Lett., 2007, 17(5), 1386-1391.
60. Wood, M.R.; Hopkins, C.R.; Brogan, J.T.; Conn, P.J.; Lindsley, C.W. Molecular switches on mGluR allosteric ligands that modulate modes of pharmacology. Biochemistry. 2011, 50(13), 2403-10.
61. Barnett, A.H.; Cradock, S.; Fisher, M.; Hall, G.; Hughes, E.; Middleton, A. Key considerations around the risks and consequences of hypoglycaemia in people with type 2 diabetes. Int. J. Clin. Pract. 2010, 64(8), 1121-1129.
62. Briscoe, C.P.; Peat, A.J.; McKeown, S.C.; Corbett, D.F.; Goetz, A.S.; Littleton, T.R.; McCoy, D.C.; Kenakin, T.P.; Andrews, J.L.; Ammala, C.; Fornwald, J.A.; Ignar, D.M.; Jenkinson, S. Pharmacolgical regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules. Br. J. Pharmacol., 2006, 148(5), 619-628.
63. Christiansen, E.; Urban, C.; Merten, N.; Liebscher, K.; Karlsen, K.K.; Hamacher, A.; Spinrath, A.; Bond, A.D.; Drewke, C.; Ullrich, S.; Kassack, M.U.; Kostenis, E.; Ulven, T. Discovery of potent and selective agonists for the free fatty acid receptor 1 (FFA1/GPR40), a potential target for the treatment of type II diabetes. J. Med. Chem., 2008, 51(22), 7061-7064.
64. Tan, C.P.; Feng, Y.; Zhou, Y.P.; Eiermann, G.J.; Petrov, A.; Zhou, C.; Lin, S.; Salituro, G.; Meinke, P.; Mosley, R.; Akiyama, T.E.; Einstein, M.; Kumar, S.; Berger, J.P.; Mills, S.G.; Thornberry, N.A.; Yang, L.; Howard, A.D. Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice. Diabetes, 2008, 57(8), 2211-2219.
65. Bharate, S.B.; Nemmani, K.V.S.; Vishwakarma, R.A. Progress in the discovery and development of small-molecule modulators of Gprotein-coupled receptor 40 (GPR40/FFA1/FFAR1): an emerging target for type 2 diabetes. Expert Opin. Ther. Patents., 2009, 19(2), 237-264.
66. Negoro, N.; Sasaki, S.; Mikami, S.; Ito, M.; Suzuki, M.; Tsujihata, Y.; Ito, R.; Harada, A.; Takeuchi, K.; Suzuki, N.; Miyazaki, J.; Santou, T.; Odani, T.; Kanzaki, N.; Funami, M.; Tanaka, T.; Kogame, A.; Matsunaga, S.; Yasuma, T.; Momose, Y. Discovery of TAK-875: a potent, selective and orally bioavailable GPR40 agonist. Med. Chem. Lett., 2010, 1, 290-294.
67. Christiansen, E.; Urban, C.; Grundmann, M.; Due-Hansen, M.E.; Hagesaether, E.; Schmidt, J.; Pardo, L.; Ullrich, S.; Kostenis, E.; Kassack, M.: Ulven, T. Identification of a potent and selective free fatty acid rReceptor 1 (FFA1/GPR40) agonist with favorable physicochemical and in vitro ADME Properties. J. Med. Chem., 2011, 54(19), 6691-6703.
68. Christiansen, E.; Due-Hansen, M.E.; Urban, C.; Grundmann, M.; Schröder, R.; Hudson, B.D.; Milligan, G.; Cawthorne, M.A.; Kostenis, E.; Kassack, M.U.; Ulven, T. Free fatty acid receptor 1 (FFA1/GPR40) agonists: mesylpropoxy appendage lowers lipophilicity and improves ADME properties. J. Med. Chem. 2012, 55(14), 6624-6628.
69. Tikhonova, I.G.; Sum, C.S.; Neumann, S.; Thomas, C.J.; Raaka, B.M.; Costanzi, S.; Gershengorn, M.C. Bidirectional.; iterative approach to the structural delineation of the functional chemoprint in GPR40 for agonist recognition. J. Med. Chem., 2007, 50(13), 2981-2989.
70. Sum, C.S.; Tikhonova, I.G.; Neumann, S.; Engel, S.; Raaka, B.M.; Costanzi, S.; Gershengorn, M.C. Identification of residues important for agonist recognition and activation in GPR40. J. Biol. Chem., 2007, 282(40), 29248-29255.
71. Kotarsky, K.; Nilsson, N.E.; Flodgren, E.; Owman, C.; Olde, B. A human cell surface receptor activated by free fatty acids and thiazolidinedione drugs. Biochem. Biophys. Res. Commun., 2003, 301(2), 406-410.
72. Smith, N.J.; Stoddart, L.A.; Devine, N.M.; Jenkins, L.; Milligan, G. The action and mode of binding of thiazolidinedione ligands at free fatty acid receptor 1. J. Biol. Chem., 2009, 284(26), 17527-17539.
73. Luo, J.; Swaminath, G.; Brown, S.P.; Zhang, J.; Guo, Q.; Chen, M.; Nguyen, K.; Tran, T.; Miao, L.; Dransfield, P.J.; Vimolratana, M.; Houze, J.B.; Wong, S.; Toteva, M.; Shan, B.; Li, F.; Zhuang, R.; Lin, D.C. A Potent Class of GPR40 Full Agonists Engages the EnteroInsular Axis to Promote Glucose Control in Rodents. PLoS One, 2012, 7(10), e46300.
74. Edfalk, S.; Steneberg, P.; Edlund, H. GPR40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion. Diabetes, 2008, 57(9), 2280-2287.
75. Greenough, W.B.; Crespin, S.R.; Steinberg, D. Hypoglycaemia and hyperinsulinaemia in response to raised free-fatty-acid levels. Lancet, 1967, 2(7530), 1334-1336.
76. El-Assaad, W.; Buteau, J.; Peyot, M.L.; Nolan, C.; Roduit, R.; Hardy, S.; Joly, E.; Dbaibo, G.; Rosenberg, L.; Prentki, M. Saturated Fatty Acids Synergize with Elevated Glucose to Cause Pancreatic β-Cell Death. Endocrinology, 2003, 144(9), 4154-4163.
77. Steneberg, P.; Rubins, N.; Bartoov-Shifman, R.; Walker, M.D.; Edlund, H. The FFA receptor GPR40 links hyperinsulinemia.; hepatic steatosis.; and impaired glucose homeostasis in mouse. Cell Metab., 2005, 1(4), 245-258.
78. Kebede, M.A.; Alquier, T.; Latour, M.G.; Poitout, V. Lipid receptors and islet function: therapeutic implicaitons? Diabetes Obes. Metab., 2009, 11(Suppl 4), 10-20.
79. Lan, H.; Hoos, L.M.; Liu, L.; Tetzloff, G.; Hu, W.; Abbondanzo, S.J.; Vassileva, G.; Gustafson, E.L.; Hedrick, J.A.; Davis, H.R. Lack of FFAR1/GPR40 does not protect mice from high-fat dietinduced metabolic disease. Diabetes, 2008, 57(11), 2999-3006.
80. Kaku, K.; Araki, T.; Yoshinaka, R. Randomized, double-blind, dose-ranging study of TAK-875, a novel GPR40 agonist, in Japanese patients with inadequately controlled type 2 diabetes. Diabetes Care, 2013, 36(2), 245-250.
81. Schmidt, J.; Smith, N.J.; Christiansen, E.; Tikhonova, I.G.; Grundmann, M.; Hudson, B.D.; Ward, R.J.; Drewke, C.; Milligan, G.; Kostenis, E.; Ulven, T. Selective orthosteric free fatty acid receptor 2 (FFA2) agonists: identification of the structural and chemical requirements for selective activation of FFA2 versus FFA3. J Biol Chem., 2011, 286(12), 10628-10640.
82. Hudson, B.D.; Christiansen, E.; Tikhonova, I.G.; Grundmann, M.; Kostenis, E.; Adams, D.R.; Ulven, T.; Milligan, G. Chemically engineering ligand selectivity at the free fatty acid receptor 2 based on pharmacological variation between species orthologs. FASEB J., 2012, 26(12), 4951-4965.
83. Hudson, B.D.; Tikhonova, I.G.; Pandey, S.K.; Ulven, T.; Milligan, G. Extracellular ionic locks determine variation in constitutive activity and ligand potency between species orthologs of the free fatty acid receptors FFA2 and FFA3. J. Biol. Chem., 2012, 287(49), 41195-411209.
84. Stoddart, L.A.; Smith, N.J.; Jenkins, L.; Brown, A.J.; Milligan, G. Conserved polar residues in transmembrane domains V.; VI.; and VII of free fatty acid receptor 2 and free fatty acid receptor 3 are required for the binding and function of short chain fatty acids. J. Biol. Chem., 2008, 283(47), 32913-32924.
85. Hoveyda, H.; Brantis, C.E.; Dutheuil, G.; Zoute, L.; Schils, D.; Bernard, J. Compounds, pharmaceutical composition and methods for use in treating metabolic disorders. International patent Application, WO 2010/066682, June 17, 2010.
86. Brantis, C.E.; Ooms, F.; Bernard, J. Novel amino acid derivatives and their use as GPR43 receptor modulators. International patent application, WO/2011/092284, August 4, 2011.
87. Lee, T.; Schwandner, R.; Swaminath, G.; Weiszmann, J.; Cardozo, M.; Greenberg, J.; Jaeckel, P.; Ge, H.; Wang, Y.; Jiao, X.; Liu, J.; Kayser, F.; Tian, H.; Li, Y. Identification and functional characterization of allosteric agonists for the G protein-coupled receptor FFA2. Mol. Pharmacol., 2008, 74(6), 1599-1609.
88. Wang, Y.; Jiao, X.; Kayser, F.; Liu, J.; Wang, Z.; Wanska, M.; Greenberg, J.; Weiszmann, J.; Ge, H.; Tian, H.; Wong, S.; Schwandner, R.; Lee, T.; Li, Y. The first synthetic agonists of FFA2: Discovery and SAR of phenylacetamides as allosteric modulators. Bioorg. Med. Chem. Lett., 2010, 20(2), 493-498.
89. Smith, N.J.; Ward, R.J.; Stoddart, L.A.; Hudson, B.D.; Kostenis, E.; Ulven, T.; Morris, J.C.; Tränkle, C.; Tikhonova, I.G.; Adams, D.R.; Milligan G. Extracellular loop 2 of the free fatty acid receptor 2 mediates allosterism of a phenylacetamide ago-allosteric modulator. Mol. Pharmacol., 2011, 80(1), 163-173.
90. Milligan, G.; Stoddart, L.A.; Smith, N.J. Agonism and allosterism: the pharmacology of the free fatty acid receptors FFA2 and FFA3. Br. J. Pharmacol., 2009, 158(1), 146-153.
91. Swaminath, G.; Jaeckel, P.; Guo, Q.; Cardozo, M.; Weiszmann, J.; Lindberg, R.; Wang, Y.; Schwandner, R.; Li, Y. Mutational analysis of G-protein coupled receptor-FFA2. Biochem. Biophys. Res. Commun., 2011, 405(1), 122-127.
92. Leonard, J.N.; Chu, Z.L.; Bruce, M.A.; Boatman, P.D. GPR41 and modulators thereof for the treatment of insulin-related disorders. International patent application, WO/2006/052566, May 18, 2006.
93. Sina, C.; Gavrilova, O.; Förster, M.; Till, A.; Derer, S.; Hildebrand, F.; Raabe, B.; Chalaris, A.; Scheller, J.; Rehmann, A.; Franke, A.; Ott, S.; Häsler, R.; Nikolaus, S.; Fölsch, U.R.; Rose-John, S.; Jiang, H.P.; Li, J.; Schreiber, S.; Rosenstiel, P. G protein-coupled receptor 43 is essential for neutrophil recruitment during intestinal inflammation. J. Immunol., 2009, 183(11), 7514-7522.
94. Maslowski, K.M.; Vieira, A.T.; Ng, A.; Kranich, J.; Sierro, F.; Yu, D.; Schilter, H.C.; Rolph, M.S.; Mackay, F.; Artis, D.; Xavier, R.J.; Teixeira, M.M.; Mackay, C.R. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature, 2009, 461(7268), 1282-1286.
95. Ge, H.; Li, X.; Weiszmann, J.; Wang, P.; Baribault, H.; Chen, J.-L.; Tian, H.; Li, Y. Activation of G protein-coupled receptor 43 in adipocytes leads to inhibition of lipolysis and suppression of plasma free fatty acids. Endocrinology, 2008, 149(9), 4519-4526.
96. Tolhurst, G.; Heffron, H.; Lam, YS.; Parker, HE.; Habib, AM.; Diakogiannaki, E.; Cameron, J.; Grosse, J.; Reimann, F.; Gribble, F.M. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes, 2012, 61(2), 364-371.
97. Vinolo, M.A.; Ferguson, G.J.; Kulkarni, S.; Damoulakis, G.; Anderson, K.; Bohlooly, Y.M.; Stephens, L.; Hawkins, P.T.; Curi, R. SCFAs induce mouse neutrophil chemotaxis through the GPR43 receptor. PLoS One, 2011, 6(6), e21205.
98. Ichimura, A.; Hirasawa, A.; Poulain-Godefroy, O.; Bonnefond, A.; Hara, T.; Yengo, L.; Kimura, I.; Leloire, A.; Liu, N.; Iida, K.; Choquet, H.; Besnard, P.; Lecoeur, C.; Vivequin, S.; Ayukawa, K.; Takeuchi, M.; Ozawa, K.; Tauber, M.; Maffeis, C.; Morandi, A.; Buzzetti, R.; Elliott, P.; Pouta, A.; Jarvelin, M.R.; Körner, A.; Kiess, W.; Pigeyre, M.; Caiazzo, R.; Van Hul, W.; Van Gaal, L.; Horber, F.; Balkau, B.; Lévy-Marchal, C.; Rouskas, K.; Kouvatsi, A.; Hebebrand, J.; Hinney, A.; Scherag, A.; Pattou, F.; Meyre, D.; Koshimizu, T.A.; Wolowczuk, I.; Tsujimoto, G.; Froguel, P. Dysfunction of lipid sensor GPR120 leads to obesity in both mouse and human. Nature, 2012, 483(7389), 350-354.
99. Taneera, J.; Lang, S.; Sharma, A.; Fadista, J.; Zhou, Y.; Ahlqvist, E.; Jonsson, A.; Lyssenko, V.; Vikman, P.; Hansson, O.; Parikh, H.; Korsgren, O.; Soni, A.; Krus, U.; Zhang, E.; Jing, X.J.; Esguerra, J.L.; Wollheim, C.B.; Salehi, A.; Rosengren, A.; Renström, E.; Groop, L. A systems genetics approach identifies genes and pathways for type 2 diabetes in human islets. Cell Metab., 2012, 16(1), 122-134.
100. Suzuki, T.; Igari, S.; Hirasawa, A.; Hata, M.; Ishiguro, M.; Fujieda, H.; Itoh, Y.; Hirano, T.; Nakagawa, H.; Ogura, M.; Makishima, M.; Tsujimoto, G.; Miyata, N. Identification of G protein-coupled receptor 120-selective agonists derived from PPARgamma agonists. J. Med. Chem., 2008, 51(23), 7640-7644.
101. Shimpukade, B.; Hudson, B.D.; Hovgaard, C.K.; Milligan, G.; Ulven, T. Discovery of a potent and selective GPR120 agonist. J. Med. Chem., 2012, 55(9), 4511-4515.
102. Sun, Q.; Hirasawa, A.; Hara, T.; Kimura, I.; Adachi, T.; Awaji, T.; Ishiguro, M.; Suzuki, T.; Miyata, N.; Tsujimoto, G. Structureactivity relationships of GPR120 agonists based on a docking simulation. Mol. Pharmacol., 2010, 78(5), 804-810.
103. Watson, S.J.; Brown, A.J.; Holliday, N.D. Differential signaling by splice variants of the human free fatty acid receptor GPR120. Mol. Pharmacol., 2012, 81(5), 631-642.
104. Arkawa, K.; Nishimura, T.; Sugimoto, Y.; Takahashi, H. Novel isoindolin-1-one derivative. International patent application, WO 2010/104195, September 16, 2010.
105. Ma, J.; Novack, A.; Nashashibi, I.; Pham, P.; Rabbat, C.J.; Song, J.; Shi, D.F.; Zhao, Z.; Choi, Y.-J.; Chen, X. Aryl GPR120 receptor agonists and uses therof. International patent application, WO 2010/048207, April 29, 2010.
106. Hashimoto, N.; Sasaki, Y.; Nakama, C.; Ishikawa, M. Novel phenyl-isoxayol-3-ol derative. United States patent application, US 2010/0130559, May 27, 2010.
107. Hara, T.; Hirasawa, A.; Sun, Q.; Sadakane, K.; Itsubo, C.; Iga, T.; Adachi, T.; Koshimizu, T.; Hashimoto, T.; Asakawa, Y.; Tsujimoto, G. Novel selective ligands for free fatty acid receptors GPR120 and GPR40. Naunyn Schmiedebergs Arch. Pharmacol., 2009, 380(3), 247-255.
108. Burns, R.N.; Moniri, N.H. Agonsim with the omega-3 faty acids α-linolenic acid and docosahexaenoic acid mediates phosphorylation of both the short and long isoforms of the human GPR120 receptor. Biochem. Biophys. Res. Commun., 2010, 396(4), 1030-1035.
109. Yousefi, S.; Cooper, P.R.; Potter, S.L.; Mueck, B.; Jarai, G. Cloning and expression analysis of a novel G-protein-coupled receptor selectively expressed on granulocytes. J. Leukoc. Biol., 2001, 69(6), 1045-1052.
110. Bouchard C.; Pagé, J.; Bédard, A.; Tremblay, P.; Vallières, L. G protein-coupled receptor 84, a microglia-associated protein expressed in neuroinflammatory conditions. Glia, 2007, 55, 790-800.
111. Nagasaki, H.; Kondo, T.; Fuchigami, M.; Hashimoto, H.; Sugimura, Y.; Ozaki, N.; Arima, H.; Ota, A.; Oiso, Y.; Hamada, Y. Inflammatory changes in adipose tissue enhance expression of GPR84; a medium-chain fatty acid receptor: TNFα enhances GPR84 expression in adipocytes. FEBS Lett., 2012, 586(4), 368-372.
112. Takeda, S.; Yamamoto, A.; Okada, T.; Matsumura, E.; Nose, E.; Kogure, K.; Kojima, S.; Haga, T. Identification of surrogate ligands for orphan G protein-coupled receptors. Life Sci., 2003, 74(2-3), 367-377.